RCKT ROCKET PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1281895 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY93.3%
TTM EPS YoY93.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-5.0%
ROA-4.1%
ROIC (approx.)-60.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.1%
Debt / equity0.09x
Current ratio7.26x
Interest coverage-100.61x
Cash quality & payout
Operating cash flow / net income9.84x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $142.01M | $171.24M | $186.34M | $165.57M | $125.48M |
| SG&A expense | $86.50M | $101.96M | $73.32M | $58.77M | $41.77M |
| Operating income | -$231.75M | -$273.20M | -$259.66M | -$224.34M | -$167.25M |
| Interest expense | $1.89M | $1.89M | $1.88M | $1.86M | $2.98M |
| Pretax income | -$223.12M | -$258.75M | — | — | — |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$223.12M | -$258.75M | -$245.59M | -$221.86M | -$169.07M |
| EBITDA | -$222.85M | -$266.00M | -$254.76M | -$220.44M | -$164.05M |
| EPS (basic) | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 |
| EPS (diluted) | -2.01 | -2.73 | -2.92 | -3.26 | -2.67 |
| Weighted avg. shares (diluted) | 111.12M | 94.81M | 84.01M | 68.15M | 63.24M |
| Balance sheet | |||||
| Cash & equivalents | $77.56M | $165.00M | $57.28M | $141.86M | $234.04M |
| Short-term investments | $111.37M | $208.70M | $317.27M | $215.88M | $156.05M |
| Inventory | $0 | — | — | — | — |
| Current assets | $192.73M | $378.18M | $378.22M | $364.06M | $392.06M |
| PP&E, net | $28.17M | $36.79M | $39.17M | $29.01M | $22.30M |
| Goodwill | $39.15M | $39.15M | $39.15M | $39.20M | $30.82M |
| Intangibles | $25.15M | $25.15M | $25.15M | $25.72M | $0 |
| Total assets | $330.45M | $527.70M | $566.34M | $551.81M | $497.02M |
| Current liabilities | $30.21M | $40.68M | $48.51M | $39.17M | $22.17M |
| Long-term debt | $0 | — | — | — | — |
| Total debt | $0 | — | — | — | — |
| Total liabilities | $53.23M | $64.47M | $73.77M | $62.12M | $42.30M |
| Shareholders' equity | $277.22M | $463.23M | $492.57M | $489.69M | $454.72M |
| Net debt | -$77.56M | — | — | — | — |
| Shares outstanding | 108.32M | 106.45M | 90.28M | 79.12M | 64.51M |
| Cash flow statement | |||||
| Operating cash flow | -$190.01M | -$209.72M | -$194.92M | -$178.14M | -$121.16M |
| Capital expenditure | $440,000 | $5.86M | $16.44M | $8.36M | $7.62M |
| Free cash flow | -$190.45M | -$215.59M | -$211.35M | -$186.50M | -$128.78M |
| Investing cash flow | $103.77M | $131.71M | -$98.07M | -$69.33M | $18.85M |
| Financing cash flow | $148,000 | $185.74M | $208.40M | $155.29M | $37.68M |
| Depreciation & amortization | $8.90M | $7.20M | $4.90M | $3.90M | $3.20M |
| Stock-based compensation | $37.06M | $43.92M | $39.41M | $31.01M | $29.24M |
| Share buybacks | — | — | — | — | $0 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.